EligibleTrials

AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses

Recruiting · NCT04392206 · Interventional (participants receive a specific treatment) · Lead sponsor: Houssam Farres, M.D.

View the official record on ClinicalTrials.gov →
Chronic kidney disease

Interventions studied

Adipose Derived Mesenchymal Stem Cells

What this trial is about

Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.

Who can take part

Age range
18 Years to 85 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.